U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940830) titled 'Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa' on April 16.
Brief Summary: The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Hemophilia A
Intervention:
DRUG: Efanesoctocog alfa
Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the...